Urinary NT-proBNP correlates with acute kidney injury in patients with V-A ECMO

https://doi.org/10.1007/s00392-025-02625-4

Andreas Leonhard Schober (Regensburg)1, A. D. Schober (Regensburg)1, U. Hubauer (Regensburg)1, M. Foltan (Regensburg)2, P. Lehn (Regensburg)3, R. Burkhardt (Regensburg)3, L. S. Maier (Regensburg)1, A. Dietl (Regensburg)1, T. Müller (Regensburg)1, M. Lubnow (Regensburg)1, C. G. Jungbauer (Regensburg)1, C. Wiest (Regensburg)1

1Universitätsklinikum Regensburg Klinik und Poliklinik für Innere Med. II, Kardiologie Regensburg, Deutschland; 2Universitätsklinikum Regensburg Herz-, Thorax- und herznahe Gefäßchirurgie Regensburg, Deutschland; 3Universitätsklinikum Regensburg Regensburg, Deutschland

 

Background:
Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) is an advanced therapy in patients with severe cardiogenic shock. Secondary organ failures are seen regularly in V-A ECMO and acute kidney injury (AKI) is one of the most frequent secondary organ failures during V-A ECMO. Urinary NT-proBNP has already shown promising results as a predictor in patients with chronic heart failure.  

Aim:
The goal of his study was to examine the prognostic value of urinary NT-proBNP levels regarding the of AKI with the necessity for renal replacement therapy (RRT) in patients with V-A ECMO.

Methods:
The current study is a prospective observational study in the university hospital Regensburg in patients with V-A ECMO from 30.08.2022 to 11.09.2024. Urinary NT-proBNP levels were measured after ECMO initiation. Initially anuric patients were excluded from this analysis. 

Results:
90 patients with VA-ECMO were included in the analysis (mean 57 years old, 63% male). 69 Patients (77%) suffered from AKI during ECMO therapy, 22 of those (24%) received RRT. ECMO-therapy lasted in mean 5 days. Patients suffering from AKI with the necessity for RRT showed significantly higher levels of urinary NT-proBNP compared to patients with AKI without RRT and those without AKI during ECMO therapy (12100 ng/l vs 1200 ng/l vs 100 ng/l, each p= 0.001). In ROC analysis urinary NT-proBNP showed promising value as a predictor for AKI (AUC 0.74, sensitivity 42%, specificity 85% for 6836 ng/l) as well as AKI with the necessity for RRT (AUC 0.71, sensitivity 46% specificity 95% for 26673 ng/l). In binary logarithmic regression the logarithm of urinary NT-proBNP was shown as an independent and statistically significant predictor for the occurrence of AKI (HR 2.32, 1.31-4.12, p=0.004 ), opposite to age, sex, the duration of ECMO therapy and the preexisting degree of renal function (each p=n.s.). For necessity for RRT due to AKI, the logarithm of urinary NT-proBNP and the duration of ECMO therapy were revealed as independent and statistically significant predictors (HR 1.81, 1.11-2.94, p=0.016 for urinary NT-proBNP; HR 1.13, 1.03-1.23, p=0.012 for ECMO duration).

Conclusion:
Patients with V-A ECMO suffer in many cases from secondary organ failure. Urinary NT-proBNP showed promising results as an independent predictor for AKI as well as AKI with the necessity for RRT.

 
Diese Seite teilen